natgillin/translations-raw huggingface dataset:
in the presence of an organic solvent and a protic acid, for a time and at a temperature sufficient to make the compound of the formula (Ia) or 
u prisutnosti organskog otapala i protične kiseline, tijekom vremena i kod temperature koja je dovoljna da se dobije spoj formule (Ia) ili
A method as claimed in any one of claims 15 to 17 wherein in process a) the acid is aqueous hydrocholoric acid or aqueous hydrobromic acid. 
Postupak prema bilo kojem zahtjevu od 15 do 17, naznačen time da je u postupku a) kiselina vodena otopina klorovodične kiseline ili vodena otopina bromovodične kiseline.
A method as claimed in claim 15, wherein in process b) the aprotic solvent is tetrahydrofuran or diethyl ether. 
Postupak prema zahtjevu 15, naznačen time, da je u postupku b) aprotično otapalo tetrahidrofuran ili dietil eter.
A pharmaceutical composition in solid dosage form, comprising (i) a therapeutically effective amount of the glassy solid form of CDDO-methyl ester of claim 1 with (ii) an edible carrier. 
Farmaceutski pripravak u krutom doznom obliku, naznačen time da sadrži (i) terapijski učinkovitu količinu staklasto-krutog CDDO metil-estera iz Zahtjeva 1 i (ii) jestivi nosač.
A method for the production of the glassy solid form of CDDO-methyl ester of claim 1, comprising (a) preparing a dimethanol solvate form of CDDO-methyl ester, having an x-ray powder diffraction pattern with characteristic peaks as shown in Table 18 and a DSC pattern as shown in Figure 24, and (b) drying the dimethanol solvate form to obtain said glassy solid form. 
Metoda za proizvodnju staklasto-krutog oblika CDDO-metilnog estera iz zahtjeva 1, naznačena time da obuhvaća (a) pripremu dimetanolnog solvata CDDO- metilnog estera, čiji rendgenski difraktogram praha ima maksimume kako je prikazano u Tablici 18 i DSC signal kako je prikazano na Slici 24, te (b) sušenje dimetanolnog solvata radi dobivanja navedenog staklasto-krutog oblika.
The glassy solid form of CDDO-methyl ester of claim 1, having a PDF spectrum with the characteristic peaks of Figure 28 from about 5 Å to about 20 Å. A pharmaceutical composition according to claim 3 for use in treating a cancerous condition. 
Staklasto-kruti oblik CDDO-metilnog estera iz Zahtjeva 1, naznačen time da ima PDF spektar s karakterističnim maksimumima iz Slike 28 od približno 5 Å do približno 20 Å. Farmaceutski pripravak sukladno Zahtjevu 3 naznačen time da je za primjenu u liječenju kanceroznih stanja.
The pharmaceutical composition according to claim 7, wherein the other anti-cancer drug is gemcitabine and the cancerous condition is pancreatic cancer. 
Farmaceutski pripravak sukladno Zahtjevu 7, naznačen time da drugi lijek protiv raka pripada skupini gemcitabina, a kancerozno stanje je rak gušterače.
A pharmaceutical composition comprising (i) a therapeutically effective amount of CDDO-methyl ester and (ii) an excipient that is a glass former, such that said composition has a Tg. 
Farmaceutski pripravak naznačen time da sadrži (i) terapijski učinkovitu količinu CDDO-metilnog estera i (ii) ekscipijent koji pomaže stvoriti staklastu fazu, tako da navedeni pripravak ima Tg.
A pharmaceutical composition of claim 13, wherein the excipient is selected from the group consisting of a hydroxpropyl methyl cellulose, a poly[1-(2-oxo-1-pyrrolidinyl)ethylene or copolymer thereof, and a methacrylic acid copolymer. 
Farmaceutski pripravak iz zahtjeva 13, naznačen time da je ekscipijent odabran iz skupine koja se sastoji od hidroksipropil metil celuloze, poli[1-(2-okso-1-pirolidinil)etilena ili njegovog kopolimera, te kopolimera metakrilne kiseline.
A pharmaceutical composition of claim 14, wherein the excipient is methacrylic acid - ethyl acrylate copolymer (1:1). 
Farmaceutski pripravak iz Zahtjeva 14, naznačen time da je ekscipijent metakrilna kiselina–etil akrilatni kopolimer (1:1).
The pharmaceutical composition for use as defined in claim 8, wherein said antagonistic anti-human IL-13 antibody is a multispecific antibody that is a bispecific antibody. 
Antagonističko protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 13, naznačeno time što je multispecifično protutijelo koje je bispecifično protutijelo.
a rest plane (2) for supporting a patient; 
plohu ležaja (2) za oslanjanje pacijenta;
a transport vehicle (6) comprising: 
transportno vozilo (6) koje obuhvaća:
at least a loading plane (60) for receiving the stretcher (1), when the support elements (3) of the stretcher (1) are both in a respective closed position, 
najmanje jednu utovarnu plohu (60) za prihvaćanje nosila (1), kada su oba nosiva elementa (3) od nosila (1) u zatvorenoj poziciji,
The system of claim 4, wherein the independent actuator (35) is a linear actuator. 
Sustav prema zahtjevu 4, naznačen time, da neovisni pokretač (35) je linearni pokretač.
The system of claim 6, wherein the means are the motorised means (35) for raising the rest plane (2). 
Sustav prema zahtjevu 6, naznačen time, da sredstva su pogonska sredstva (35) za podizanje plohe ležaja (2).
The system of claim 1, wherein the first support element (3) displaces from the open position to the closed position, rotating in an upwards direction towards the loading plane (60) of the transport vehicle (6). 
Sustav prema zahtjevu 1, naznačen time, da se prvi nosivi element (3) premješta iz otvorene pozicije u zatvorenu poziciju, rotirajući prema gore i u smjeru prema utovarnoj plohi (60) transportnog vozila (6).
A compound according to claim 1, which is a salt of (E)-3-[1-(4-dimetylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide with any acid selected from the group consisting of phosphoric acid, sulphuric acid, acetic acid, citric acid, maleic acid, fumaric acid, succinic acid, oxalic acid, stearic acid, lauric acid, methanesulphonic acid, L-ascorbic acid, L-aspartic acid, ethanesulfonic acid, glutamic acid, lactic acid such as D-lactic acid or L-lactic acid, malonic acid, cyclamic acid, salicyclic acid, capronic acid, glutaric acid, palmitic acid, toluenesulphonic acid, benzenesulfonic acid and naphthalene-2-sulfonic acid, or with a base selected from the group consisting of a sodium salt, a guanidinium salt, a magnesium salt, a calcium salt, an ammonium salt and a triethylammonium salt; 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je sol (E)-3-[1-(4-dimetilaminometilbenzensulfonil)-1H-pirol-3-il]-N-hidroksiakrilamida s bilo kojom od kiselina koje se bira iz skupine koju čine fosforna kiselina, sumporna kiselina, octena kiselina, limunska kiselina, maleinska kiselina, fumarna kiselina, jantarna kiselina, oksalna kiselina, stearinska kiselina, laurinska kiselina, metansulfonska kiselina, l-askorbinska kiselina, l-asparaginska kiselina, etansulfonska kiselina, glutaminska kiselina, mliječna kiselina, primjerice d-mliječna kiselina ili l-mliječna kiselina, malonska kiselina, ciklaminska kiselina, salicilna kiselina, kapronska kiselina, glutarna kiselina, palmitinska kiselina, toluensulfonska kiselina, benzensulfonska kiselina i naftalen-2-sulfonska kiselina, ili s bazom koju se bira iz skupine koju čine natrijeva sol, gvanidinijeva sol, magnezijeva sol, kalcijeva sol, amonijeva sol i trietilamonijeva sol; ili njegov hidrat.
A compound according to claim 1, which is an acid addition salt of (E)-3-[1-(4-dimetylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide with any acid selected from the group consisting of phosphoric acid, sulphuric acid, acetic acid, citric acid, maleic acid, fumaric acid, succinic acid, oxalic acid, toluenesulphonic acid and methanesulphonic acid, or a hydrate thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselinska adicijska sol (E)-3-[1-(4-dimetilaminometilbenzensulfonil)-1H-pirol-3-il]-N-hidroksiakrilamida s bilo kojom od kiselina koje se bira iz skupine koju čine fosforna kiselina, sumporna kiselina, octena kiselina, limunska kiselina, maleinska kiselina, fumarna kiselina, jantarna kiselina, oksalna kiselina, toluensulfonska kiselina i metansulfonska kiselina, ili njegov hidrat.
A compound according to claim 1, which is an acid addition salt of (E)-3-[1-(4-dimetylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide with any add selected from the group consisting of benzenesulfonic acid, ethanesulfonic acid, glutamic acid, malonic acid, naphthalene-2-sulfonic acid, salicyclic acid, capronic acid, glutaric acid and palmitic acid, or a hydrate thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselinska adicijska sol (E)-3-[1-(4-dimetilaminometilbenzensulfonil)-1H-pirol-3-il]-N-hidroksiakrilamida s bilo kojim add kojeg se bira iz skupine koju čine benzensulfonska kiselina, etansulfonska kiselina, glutaminska kiselina, malonska kiselina, naftalen-2-sulfonska kiselina, salicilna kiselina, kapronska kiselina, glutarna kiselina i palmitinska kiselina, ili njegov hidrat.
A compound according to claim 1, which is an acid addition salt of (E)-3-[1-(4-dimetylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide with any acid selected from the group consisting of phosphoric acid, maleic acid, oxalic acid, malonic acid and methanesulphonic acid, or a hydrate thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselinska adicijska sol (E)-3-[1-(4-dimetilaminometilbenzensulfonil)-1H-pirol-3-il]-N-hidroksiakrilamida s bilo kojom od kiselina koje se bira iz skupine koju čine fosforna kiselina, maleinska kiselina, oksalna kiselina, malonska kiselina i metansulfonska kiselina, ili njegov hidrat.
A compound according to claim 1, which is an acid addition salt of (E)-3-[1-(4-dimetylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide with any acid selected from the group consisting of methanesulphonic acid, p-toluenesulphonic acid, benzenesulfonic acid, ethanesulfonic acid, naphthalene-2-sulfonic acid and palmitic acid, or a hydrate thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselinska adicijska sol (E)-3-[1-(4-dimetilaminometilbenzensulfonil)-1H-pirol-3-il]-N-hidroksiakrilamida s bilo kojom od kiselina koje se bira iz skupine koju čine metansulfonska kiselina, p-toluensulfonska kiselina, benzensulfonska kiselina, etansulfonska kiselina, naftalen-2-sulfonska kiselina i palmitinska kiselina, ili njegov hidrat.
A compound according to claim 1, which is an acid addition salt of (E)-3-[1-(4-dimetylaminomethyl-benzenesulfonyl)-1H-pyrroi-3-yl]-N-hydroxy-acrylamide with methanesulphonic acid, or a hydrate thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselinska adicijska sol (E)-3-[1-(4-dimetilaminometilbenzensulfonil)-1H-pirol-3-il]-N-hidroksiakrilamida s metansulfonskom kiselinom, ili njegov hidrat.
A pharmaceutical composition comprising a salt of a compound according to any of the claims 1 to 9 together with customary pharmaceutical diluents, excipients and/or carriers. 
Farmaceutski pripravak, naznačen time što sadrži sol spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, kao i uobičajene farmaceutske razrjeđivače, pomoćne tvari i/ili podloge.
Use of a salt of a compound according to any of the claims 1 to 9 for the manufacture of pharmaceutical compositions for treating, preventing or ameliorating benign or malignant neoplasia, such as e.g. cancer. 
Upotreba soli spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što je navedena sol namijenjena proizvodnji farmaceutskih pripravaka za liječenje, sprječavanje ili ublažavanje dobroćudnih ili zloćudnih novotvorina, poput raka.
A salt of a compound according to any of the claims 1 to 9 for use in a method for treating, preventing or ameliorating hyperproliferative diseases of benign or malignant behaviour and/or disorders responsive to induction of apoptosis, such as, for example, benign or malignant neoplasia, e.g. cancer, in a patient 
Sol spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što je namijenjena upotrebi u postupku liječenja, sprječavanja ili ublažavanja hiperproliferativnih bolesti dobroćudnog ili zloćudnog karaktera i/ili poremećaja koji reagiraju na induciranje apoptoze, poput dobroćudnih ili zloćudnih novotvorina, primjerice raka, kod pacijenta.
A salt of a compound according to any of the claims 1 to 9 for use in a method for treating diseases responsive or sensitive to inhibition of histone deacetylase activity in a patient. 
Sol spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što je namijenjena upotrebi u postupku liječenja bolesti koje reagiraju na ili su osjetljive na inhibiranje aktivnosti histon-deacetilaze kod pacijenta.
A combination comprising a first active ingredient, which is at least one salt of a compound according to any of the claims 1 to 9, and a second active ingredient, which is at least one anti-cancer agent selected from the group consisting of chemotherapeutic anti-cancer agents and target-specific anti-cancer agents, for separate, sequential, simultaneous, concurrent or chronologically staggered use in therapy, such as e.g. in therapy of benign or malignant neoplasia, e.g. cancer. 
Kombinacija, naznačena time što sadrži prvi aktivni sastojak, koji je najmanje jedna sol spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, i drugi aktivni sastojak, koji je najmanje jedno sredstvo protiv raka, kojeg se bira iz skupine koju čine kemoterapijska sredstva protiv raka i ciljno specifična sredstva protiv raka, namijenjen odvojenoj, uzastopnoj, istodobnoj, paralelnoj ili kronološki razdijeljenoj upotrebi u terapiji, primjerice u terapiji dobroćudnih ili zloćudnih novotvorina, primjerice raka.
A salt of a compound according to any of the claims 1 to 9 for use in a method for treating, preventing or ameliorating hyperproliferative diseases and/or disorders responsive to induction of apoptosis, such as, for example, benign or malignant neoplasia, e.g. cancer, in a patient comprising administering separately, simultaneously, concurrently, sequentially or chronologically staggered to said patient in need thereof an amount of a first active compound, which is a salt of a compound according to any of the claims 1 to 9, and an amount of at least one second active compound, said second active compound being an anti-cancer agent selected from the group consisting of chemotherapeutic anti-cancer agents and target-specific anti-cancer agents, wherein the amounts of the first active compound and said second active compound result in a therapeutic effect. 
Sol spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što je namijenjena upotrebi u postupku liječenja, sprječavanja ili ublažavanja hiperproliferativnih bolesti i/ili poremećaja koji reagiraju na induciranje apoptoze, poput dobroćudnih ili zloćudnih novotvorina, primjerice raka, kod pacijenta, gdje se odvojeno, istodobno, paralelno, uzastopno ili kronološki razdijeljeno na navedenom pacijentu kojem je to potrebno primijenjuje količinu prvog aktivnog spoja, koji je sol spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, i količinu najmanje jednog drugog aktivnog spoja, gdje je navedeni drugi aktivni spoj sredstvo protiv raka, kojeg se bira iz skupine koju čine kemoterapijska sredstva protiv raka i ciljno specifična sredstva protiv raka, gdje količine prvog aktivnog spoja i navedenog drugog aktivnog spoja rezultiraju terapijskim učinkom.
A salt of a compound according to any of the claims 1 to 9 for use in a method according to any of the claims 14 and 17, in which said cancer is selected from the group consisting of cancer of the breast, bladder, bone, brain, central and peripheral nervous system, colon, endocrine glands, esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, mesothelioma, sarcoma, ovary, pancreas, prostate, rectum, renal, small intestine, soft tissue, testis, stomach, skin, ureter, vagina and vulva; 
Sol spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što je namijenjena upotrebi u postupku u skladu s bilo kojim od patentnih zahtjeva 14 i 17, gdje se navedeni rak bira iz skupine koju čine rak dojke, mokraćnog mjehura, kostiju, mozga, središnjeg i perifernog živčanog sustava, debelog crijeva, endokrinih žlijezda, jednjaka, endometrija, germinativnih stanica, glave i vrata, bubrega, jetre, pluća, larinksa i hipofarinksa, mezoteliom, sarkom, rak jajnika, gušterače, prostate, rektuma, bubrežnog tkiva, tankog crijeva, mekog tkiva, testisa, želuca, kože, mokraćovoda, vagine i vulve;
inherited cancers, retinomblastoma and Wilms tumor; 
nasljedni oblici raka, retinomblastom i Wilmsov tumor;
leukemia, lymphoma, non-Hodgkins disease, chronic and acute myeloid leukaemia, acute lymphoblastic leukemia, Hodgkins disease, multiple myeloma and T-cell lymphoma; 
leukemija, limfom, nehodgkinovska bolest, kronična i akutna mijeloidna leukemija, akutna limfoblastična leukemija, Hodgkinova bolest, multipli mijelom i limfom T-stanica;
myelodysplastic syndrome, plasma cell neoplasia, paraneoplastic syndromes, cancers of unknown primary site and AIDS related malignancies. 
mijelodisplastični sindrom, plazmacitne novotvorine, paraneoplastični sindromi, rak nepoznatog primarnog sijela i malignomi vezani uz AIDS.
The use according to claim 13, in which said cancer is selected from the group consisting of cancer of the breast, bladder, bone, brain, central and peripheral nervous system, colon, endocrine glands, esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, mesothelioma, sarcoma, ovary, pancreas, prostate, rectum, renal, small intestine, soft tissue, testis, stomach, skin, ureter, vagina and vulva; inherited cancers, retinomblastoma and Wilms tumor; leukemia, lymphoma, non-Hodgkins disease, chronic and acute myeloid leukaemia, acute lymphoblastic leukemia, Hodgkins disease, multiple myeloma and T-cell lymphoma; myelodysplastic syndrome, plasma cell neoplasia, paraneoplastic syndromes, cancers of unknown primary site and AIDS related malignancies. 
Upotreba u skladu s patentnim zahtjevom 13, naznačena time što se navedeni rak bira iz skupine koju čine rak dojke, mokraćnog mjehura, kostiju, mozga, središnjeg i perifernog živčanog sustava, debelog crijeva, endokrinih žlijezda, jednjaka, endometrija, germinativnih stanica, glave i vrata, bubrega, jetre, pluća, larinksa i hipofarinksa, mezoteliom, sarkom, rak jajnika, gušterače, prostate, rektuma, bubrežnog tkiva, tankog crijeva, mekog tkiva, testisa, želuca, kože, mokraćovoda, vagine i vulve; nasljedni oblici raka, retinomblastom i Wilmsov tumor; leukemija, limfom, nehodgkinovska bolest, kronična i akutna mijeloidna leukemija, akutna limfoblastična leukemija, Hodgkinova bolest, multipli mijelom i limfom T-stanica; mijelodisplastični sindrom, plazmacitne novotvorine, paraneoplastični sindromi, rak nepoznatog primarnog sijela i malignomi vezani uz AIDS.
The combination according to claim 16, in which said cancer is selected from the group consisting of cancer of the breast, bladder, bone, brain, central and peripheral nervous system, colon, endocrine glands, esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, mesothelioma, sarcoma, ovary, pancreas, prostate, rectum, renal, small intestine, soft tissue, testis, stomach, skin, ureter, vagina and vulva; inherited cancers, retinomblastoma and Wilms tumor; leukemia, lymphoma, non-Hodgkins disease, chronic and acute myeloid leukaemia, acute lymphoblastic leukemia, Hodgkins disease, multiple myeloma and T-cell lymphoma; myelodysplastic syndrome, plasma cell neoplasia, paraneoplastic syndromes, cancers of unknown primary site and AIDS related malignancies. 
Kombinacija u skladu s patentnim zahtjevom 16, naznačena time što se navedeni rak bira iz skupine koju čine rak dojke, mokraćnog mjehura, kostiju, mozga, središnjeg i perifernog živčanog sustava, debelog crijeva, endokrinih žlijezda, jednjaka, endometrija, germinativnih stanica, glave i vrata, bubrega, jetre, pluća, larinksa i hipofarinksa, mezoteliom, sarkom, rak jajnika, gušterače, prostate, rektuma, bubrežnog tkiva, tankog crijeva, mekog tkiva, testisa, želuca, kože, mokraćovoda, vagine i vulve; nasljedni oblici raka, retinomblastom i Wilmsov tumor; leukemija, limfom, nehodgkinovska bolest, kronična i akutna mijeloidna leukemija, akutna limfoblastična leukemija, Hodgkinova bolest, multipli mijelom i limfom T-stanica; mijelodisplastični sindrom, plazmacitne novotvorine, paraneoplastični sindromi, rak nepoznatog primarnog sijela i malignomi vezani uz AIDS.
The composition of claim 1, wherein said compound is present in said composition in an amount of 20 - 90% by weight. 
Smjesa prema zahtjevu 1, gdje je spoj prisutan u smjesi u količini od 20 - 90% težinski.
The composition of claim 3, wherein said compound is present in an amount of 60-75% by weight. 
Smjesa prema zahtjevu 3, gdje je spoj prisutan u smjesi u količini od 60-75% težinski.
The composition of claim 1, wherein said HPMC has a viscosity of at least about 2000 cP, at least about 3000 cP or at least about 4000 cP. 
Smjesa prema zahtjevu 1, gdje HPMC ima viskoznost od najmanje oko 2000 cP, najmanje oko 3000 cP ili najmanje oko 4000 cP.
The composition of claim 1, further comprising one or more additional excipients selected from the group consisting of microcrystalline cellulose, silicon dioxide, and magnesium stearate. 
Smjesa prema zahtjevu 1, koja dalje sadrži jednu ili više dodatnih pomoćnih tvari izabranih iz skupine koja obuhvaća mikrokristaliničnu celulozu, silicijev dioksid i magnezijev stearat.
The composition of claim 8, wherein said additional excipients are present in an amount of 15% by weight of said composition. 
Smjesa prema zahtjevu 8, gdje dodatnih pomoćnih tvari ima u količini od 15% težinski.
The composition of claim 1, wherein said viscosity of the HMPC does not exceed about 120,000 cP. 
Smjesa prema zahtjevu 1, gdje viskoznost HMPC ne prelazi oko 120,000 cP.
The composition of claim 1, wherein said compound is in the form of a tris salt. 
Smjesa prema zahtjevu 1, gdje je spoj u obliku tris soli.
The composition of claim 1, useful for treating infection by HIV, which additionally comprises an antiviral effective amount of an AIDS treatment agent selected from the group consisting of: 
Smjesa prema zahtjevu 1, korisna u liječenju HIV infekcije, a dodatno sadrži antivirusnu učinkovitu količinu sredstva za liječenje AIDS-a izabranog iz skupine koja obuhvaća:
an AIDS antiviral agent; 
AIDS antivirusno sredstvo;
another HIV entry inhibitor. 
drugi inhibitor ulaska HIV-a.
The composition for use according to claim 14, comprising administering to said mammal an antiviral effective amount of said composition, in combination with an antiviral effective amount of an AIDS treatment agent selected from the group consisting of an AIDS antiviral agent; an anti-infective agent; an immunomodulator; and another HIV entry inhibitor. 
Smjesa za uporabu prema zahtjevu 14, obuhvaća primjenu sisavcu antivirusne učinkovite količine smjese, u kombinaciji s antivirusnom učinkovitom količinom sredstva za liječenje AIDS-a izabranih iz skupine koja obuhvaća AIDS antivirusno sredstvo; anti-infektivno sredstvo; imunomodulator; i drugi inhibitor ulaska HIV-a.
A crystalline hydrogen succinate salt of Compound I defined in claim 1. 
Kristalinična vodik sukcinatna sol Spoja I prema zahtjevu 1.
Use of a salt according to any of claims 1-8 in the preparation of a medicament for the treatment of a disease selected from the group consisting of a disease involving psychotic symptoms, anxiety disorders, affective disorders including depression, sleep disturbances, migraine, neuroleptic-induced parkinsonism, or abuse disorders, e.g . 
Uporaba soli prema bilo kojem od zahtjeva 1-8 u pripremi lijeka za liječenje bolesti izabrane iz skupine koja obuhvaća bolest koja uključuje psihotične simptome, anksiozne poremećaje, afektivne poremećaje uključujući depresiju, poremećaje spavanja, migrenu, neuroleptički inducirani parkinsonizam ili ovisnosti npr.
cocaine abuse, nicotine abuse, or alcohol abuse. 
o kokainu, nikotinu ili alkoholu.
Use of a salt according to any of claims 1-8 in the preparation of a medicament for the treatment of schizophrenia or other psychotic disorders. 
Uporaba soli prema bilo kojem od zahtjeva 1-8 u pripremi lijeka za liječenje shizofrenije ili drugih psihotičnih poremećaja.